Addex Therapeutics Ltd (ADXN)

Market Cap	25.34M
Revenue (ttm)	1.96M
Net Income (ttm)	-12.57M
Shares Out	1.64M
EPS (ttm)	-0.15
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	5,071
Open	16.81
Previous Close	15.55
Day's Range	15.20 - 16.10
52-Week Range	5.00 - 27.90
Beta	1.76
Analysts	n/a
Price Target	n/a
Earnings Date	Apr 18, 2024

About ADXN

Addex Therapeutics Ltd, a development-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule pharmaceutical products for central nervous system (CNS) disorders in Switzerland. The company focuses on the discovery of G-protein coupled receptors. Its lead programs include Dipraglurant for the treatment of Parkinson's disease levodopa-induced dyskinesia, and dystonia; ADX71149 for epilepsy and undisclosed CNS disorders; and GABAB PAM for pain, anxiety, and addiction. It has license and collaboration agreement with ...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2002
• Employees: 23
• Stock Exchange: NASDAQ
• Ticker Symbol: ADXN

Financial Performance

In 2023, ADXN's revenue was 1.65 million, an increase of 13.99% compared to the previous year's 1.44 million. Losses were -10.56 million, -49.26% less than in 2022.

Financial numbers in CHF